FGF23 and hyperphosphatemia: It is most likely that in the near future we aim at specific treatment options for hyperphosphatemia, chronic microinflammation, and increased FGF-23 levels and may be also MC chymase inhibition in patients with CKD that might help to lower the exceedingly high cardiovascular risk in this particular population group.